-
公开(公告)号：US20060045796A1
公开(公告)日：2006-03-02
申请号：US10924579
申请日：2004-08-24
Applicant: Heinz Anderle , Peter Matthiessen , Hans-Peter Schwarz , Peter Turecek , Thomas Kreil , Daniel Boggs
Inventor： Heinz Anderle , Peter Matthiessen , Hans-Peter Schwarz , Peter Turecek , Thomas Kreil , Daniel Boggs
CPC classification number: A61L2/10 , A23L3/26 , A23L3/28 , A61L2/0011 , A61L2/28 , G01N21/33 , H05B3/0052
Abstract: The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivate microorganisms present in a biological fluid, preferably a non-transparent fluid. Moreover, there is provided a method for the inactivation of microorganism in a biological fluid in a flow-through-reactor. Moreover, the invention advantageously provides a flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate microorganisms present in a biological fluid in a batch reactor.
-
12.发明授权公开(公告)号：US06777390B1
公开(公告)日：2004-08-17
申请号：US09719945
申请日：2001-02-20
Applicant: Peter Matthiessen , Peter Turecek , Hans-Peter Schwarz
Inventor： Peter Matthiessen , Peter Turecek , Hans-Peter Schwarz
IPC: A61K3800
CPC classification number: C12N9/6437 , A61K38/00 , C12Y304/21021
Abstract: Stable pharmaceutical preparations containing blood coagulation Factor VII is disclosed. The pharmaceutical preparations containing blood coagulation Factor VII are free of coagulation inhibitors and are stable over a wide range of environmental conditions. Also provided are blood coagulation Factor VII preparations having a minimum activity of 50 Units/mg of protein that contain less than 5% activated blood coagulation Factor VII (Factor VIIa). The blood coagulation Factor VII containing preparations may also contain other blood coagulation factors and are free from detectable transmissible human pathogens.
Abstract translation: 公开了含有凝血因子VII的稳定的药物制剂。 含有凝血因子VII的药物制剂不含凝血抑制剂，并且在宽范围的环境条件下是稳定的。 还提供具有最小活性为50单位/ mg蛋白质的含有少于5％的活化凝血因子VII（因子VIIa）的凝血因子Ⅶ制剂。 含有凝血因子Ⅶ的制剂还可含有其他凝血因子，并且不含可检测的可传播的人类病原体。
-
13.发明授权Method for the validatable inactivation of pathogens in a biological fluid by irradiation 有权通过照射可以有效灭活生物体液中病原体的方法公开(公告)号：US08986607B2
公开(公告)日：2015-03-24
申请号：US10547172
申请日：2004-02-27
Applicant: Heinz Anderle , Peter Matthiessen , Hans-Peter Schwarz , Peter Turecek , Thomas Kreil , Daniel R. Boggs
Inventor： Heinz Anderle , Peter Matthiessen , Hans-Peter Schwarz , Peter Turecek , Thomas Kreil , Daniel R. Boggs
IPC: A61L2/00 , C12N13/00 , G01J1/08 , A61L2/10 , A61L2/28 , G01J1/42 , G01J1/48 , A61M1/36 , C02F1/32
CPC classification number: G01J1/08 , A61L2/0011 , A61L2/0017 , A61L2/0052 , A61L2/10 , A61L2/28 , A61L2202/22 , A61M1/3681 , A61M1/3683 , A61M2205/053 , C02F1/32 , C02F2201/326 , G01J1/42 , G01J1/48
Abstract: A validatable method for determining a photochemically effective dose for inactivating pathogens in a fluid sample is described herein. In particular, the instant invention covers methods for determining a photochemically effective dose sufficient to inactivate pathogens in a biological sample while leaving biologically active substances of interest unaffected. A batch irradiation reactor effective for inactivating pathogens in biological samples is also described.
Abstract translation: 本文描述了用于确定用于灭活流体样品中病原体的光化学有效剂量的可验证方法。 特别地，本发明包括确定足以灭活生物样品中的病原体的光化学有效剂量同时使感兴趣的生物活性物质不受影响的方法。 还描述了有效用于灭活生物样品中的病原体的批量照射反应器。
-
14.发明授权Ethanol dependence of alpha1 antitrypsin C-terminal lys truncation by basic carboxypeptidases 有权乙酸依赖的α1抗胰蛋白酶C-末端裂解基本羧肽酶公开(公告)号：US08772240B2
公开(公告)日：2014-07-08
申请号：US11749944
申请日：2007-05-17
Applicant: Peter Matthiessen , Alfred Weber , Peter Turecek , Hans-Peter Schwarz
Inventor： Peter Matthiessen , Alfred Weber , Peter Turecek , Hans-Peter Schwarz
CPC classification number: C07K1/30 , A61K38/57 , C07K14/473 , C07K14/8125
Abstract: Methods of preparing alpha-1-antiproteinase inhibitor and controlling the amount of des-lys alpha-1-antiproteinase inhibitor in the preparation, and compositions comprising the same, as well as methods of treatment using the same are provided.
Abstract translation: 提供了制备α-1-抗蛋白酶抑制剂并控制制剂中des-lysα-1-抗蛋白酶抑制剂的量的方法，以及包含其的组合物以及使用其的治疗方法。
-
公开(公告)号：US08623352B2
公开(公告)日：2014-01-07
申请号：US12887424
申请日：2010-09-21
Applicant: Peter Matthiessen , Peter L. Turecek , Hans-Peter Schwarz
Inventor： Peter Matthiessen , Peter L. Turecek , Hans-Peter Schwarz
CPC classification number: A61K38/4886 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/22 , A61K47/26 , C12Y304/24087
Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
Abstract translation: 本发明涉及具有增强或期望性质的ADAMTS13制剂。 因此，本发明提供了适用于药物给药的ADAMTS13的液体和冻干制剂。 除了其它方面，本发明还提供了治疗受试者中与VWF和/或ADAMTS13功能障碍相关的各种疾病和病症的方法。 本文还提供了包含可用于治疗各种疾病和病症的ADAMTS13制剂的试剂盒。
-
Patent Agency Ranking
公开(公告)号：US20130171671A1
公开(公告)日：2013-07-04
申请号：US13638919
申请日：2011-04-08
Applicant: Peter Matthiessen
Inventor： Peter Matthiessen
IPC: C12Q1/56
CPC classification number: C12Q1/56 , C07K14/755 , C07K14/8128 , G01N33/6803 , G01N2333/755 , G01N2333/8128 , G06F17/10 , G06F17/11 , G06F19/12 , G06F19/16
Abstract: The present invention relates to a method for determining the highest temperature that is suitable for performing accelerated protein stability studies, as well as to a method for modeling real-time protein stability from accelerated stability data generated at said temperature.
Abstract translation: 本发明涉及一种用于确定适合进行加速蛋白质稳定性研究的最高温度的方法，以及用于通过在所述温度下产生的加速稳定性数据建模实时蛋白质稳定性的方法。
-
公开(公告)号：US20110229455A1
公开(公告)日：2011-09-22
申请号：US12887424
申请日：2010-09-21
Applicant: Peter Matthiessen , Peter L. Turecek , Hans-Peter Schwarz
Inventor： Peter Matthiessen , Peter L. Turecek , Hans-Peter Schwarz
CPC classification number: A61K38/4886 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/22 , A61K47/26 , C12Y304/24087
Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
Abstract translation: 本发明涉及具有增强或期望性质的ADAMTS13制剂。 因此，本发明提供了适用于药物给药的ADAMTS13的液体和冻干制剂。 除了其它方面，本发明还提供了治疗受试者中与VWF和/或ADAMTS13功能障碍相关的各种疾病和病症的方法。 本文还提供了包含可用于治疗各种疾病和病症的ADAMTS13制剂的试剂盒。
-
18.发明申请ETHANOL DEPENDENCE OF ALPHA1 ANTITRYPSIN C-TERMINAL LYS TRUNCATION BY BASIC CARBOXYPEPTIDASES 有权基于羧基磷酸酯的ALPHA1抗体终止子宫切除的乙醇依赖公开(公告)号：US20070274976A1
公开(公告)日：2007-11-29
申请号：US11749944
申请日：2007-05-17
Applicant: Peter Matthiessen , Alfred Weber , Peter Turecek , Hans-Peter Schwarz
Inventor： Peter Matthiessen , Alfred Weber , Peter Turecek , Hans-Peter Schwarz
CPC classification number: C07K1/30 , A61K38/57 , C07K14/473 , C07K14/8125
Abstract: The present invention provides methods of preparing alpha-1-antiproteinase inhibitor and controlling the amount of des-lys alpha-1-antiproteinase inhibitor in the preparation, and compositions comprising the same, as well as methods of treatment using the same.
Abstract translation: 本发明提供制备α-1-抗蛋白酶抑制剂并控制制剂中des-lysα-1-抗蛋白酶抑制剂的量的方法，以及包含其的组合物以及使用其的治疗方法。
-
19.发明申请公开(公告)号：US20060257877A1
公开(公告)日：2006-11-16
申请号：US10547172
申请日：2004-02-27
Applicant: Heinz Anderle , Peter Matthiessen , Hans-Peter Schwarz , Peter Turecek , Thomas Kreil , Daniel Boggs
Inventor： Heinz Anderle , Peter Matthiessen , Hans-Peter Schwarz , Peter Turecek , Thomas Kreil , Daniel Boggs
IPC: C12Q1/68
CPC classification number: G01J1/08 , A61L2/0011 , A61L2/0017 , A61L2/0052 , A61L2/10 , A61L2/28 , A61L2202/22 , A61M1/3681 , A61M1/3683 , A61M2205/053 , C02F1/32 , C02F2201/326 , G01J1/42 , G01J1/48
Abstract: A validatable method for determining a photochemically effective dose for inactivating pathogens in a fluid sample is described herein. In particular, the instant invention covers methods for determining a photochemically effective dose sufficient to inactivate pathogens in a biological sample while leaving biologically active substances of interest unaffected. A batch irradiation reactor effective for inactivating pathogens in biological samples is also described.
-
20.发明授权公开(公告)号：US06974792B2
公开(公告)日：2005-12-13
申请号：US09963341
申请日：2001-09-24
Applicant: Erwin Mattes , H. Peter Matthiessen
Inventor： Erwin Mattes , H. Peter Matthiessen
IPC: A61K38/55 , A61K38/00 , A61P1/16 , A61P11/00 , A61P43/00 , C07K1/16 , C07K14/81 , C12N7/04 , C12N9/50
CPC classification number: C07K14/8125 , A61K38/00
Abstract: A native, chromatographically purified α1-AT preparation having a purity of at least 0.7 PU/mg protein and a relative plasma α1-AT activity of at least 120% is disclosed. The ratio of active to inactive α1-AT is higher than in plasma.Furthermore, a method of producing this preparation is disclosed, as well as the use of a carrier material, e.g. an inorganic carrier material such as hydroxylapatite for separating active α1-AT from inactive α1-AT.
Abstract translation: 公开了具有至少0.7PU / mg蛋白纯度和至少120％的相对血浆α1-AT活性的天然色谱纯化的α1-AT制剂。 活性与无活性α1-AT的比例高于血浆。 此外，公开了制备该制剂的方法，以及载体材料的使用，例如， 用于分离活性α1-AT和无活性α1-AT的无机载体材料，例如羟基磷灰石。
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.029 seconds)
